Updated : Jun 27, 2017 in

Chantix®

General:
Nausea was the most common adverse event associated with CHANTIX® treatment. Nausea was generally described as mild or moderate and often transient; however, for some subjects, it was persistent over several months. The incidence of nausea was dose-dependent. Initial dose titration was beneficial in reducing the occurrence of nausea. Nausea was reported by approximately 30% of patients treated with CHANTIX® 1 mg BID after an initial week of dose titration. In patients taking CHANTIX® 0.5 mg BID, the incidence of nausea was 16% following initial titration.

Chantix®

Approximately 3% of subjects treated with CHANTIX® 1 mg BID in studies involving 12 weeks of treatment discontinued treatment prematurely because of nausea. For patients with intolerable nausea, dose reduction should be considered. Effect of smoking cessation: Physiological changes resulting from smoking cessation, with or without treatment with CHANTIX®, may alter the pharmacokinetics or pharmacodynamics of some drugs, for which dosage adjustment may be necessary (examples include theophylline, warfarin and insulin).

Drug Interactions:
Based on varenicline characteristics and clinical experience to date, CHANTIX® has no clinically meaningful pharmacokinetic drug interactions.

Carcinogenesis, Mutagenesis, Impairment of Fertility:
Carcinogenesis. Lifetime carcinogenicity studies were performed in CD-1 mice and Sprague-Dawley rats. There was no evidence of a carcinogenic effect in mice administered varenicline by oral gavage for 2 years at doses up to 20 mg/kg/day (47 times the maximum recommended human daily exposure based on AUC). Rats were administered varenicline (1, 5, and 15 mg/kg/day) by oral gavage for 2 years. In male rats (n = 65 per sex per dose group), incidences of hibernoma (tumor of the brown fat) were increased at the mid dose (1 tumor, 5 mg/kg/day, 23 times the maximum recommended human daily exposure based on AUC) and maximum dose (2 tumors, 15 mg/kg/day, 67 times the maximum recommended human daily exposure based on AUC). The clinical relevance of this finding to humans has not been established. There was no evidence of carcinogenicity in female rats. Mutagenesis. Varenicline was not genotoxic, with or without metabolic activation, in the following assays: Ames bacterial mutation assay; mammalian CHO/HGPRT assay; and tests for cytogenetic aberrations in vivo in rat bone marrow and in vitro in human lymphocytes. Impairment of fertility. There was no evidence of impairment of fertility in either male or female Sprague-Dawley rats administered varenicline succinate up to 15 mg/kg/day (67 and 36 times, respectively, the maximum recommended human daily exposure based on AUC at 1 mg (BID). However, a decrease in fertility was noted in the offspring of pregnant rats who were administered varenicline succinate at an oral dose of 15 mg/kg/day (36 times the maximum recommended human daily exposure based on AUC at 1 mg (BID). This decrease in fertility in the offspring of treated female rats was not evident at an oral dose of 3 mg/kg/day (9 times the maximum recommended human daily exposure based on AUC at 1 mg BID).

Pregnancy:
Pregnancy Category C. Varenicline succinate was not teratogenic in rats and rabbits at oral doses up to 15 and 30 mg/kg/day, respectively (36 and 50-times the maximum recommended human daily exposure based on AUC at 1 mg BID, respectively).

Nonteratogenic effects:
Varenicline succinate has been shown to have an adverse effect on the fetus in animal reproduction studies. Administration of varenicline succinate to pregnant rabbits resulted in reduced fetal weights at an oral dose of 30 mg/kg/day (50 times the human AUC at 1 mg BID); this reduction was not evident following treatment with 10 mg/kg/day (23 times the maximum recommended daily human exposure based on AUC). In addition, in the offspring of pregnant rats treated with varenicline succinate there were decreases in fertility and increases in auditory startle response at an oral dose of 15 mg/kg/day (36 times the maximum recommended human daily exposure based on AUC at 1 mg BID). There are no adequate and well-controlled studies in pregnant women. CHANTIX® should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing mothers:
Although it is not known whether this drug is excreted in human milk, animal studies have demonstrated that varenicline can be transferred to nursing pups. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from CHANTIX%reg;, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the other.

Labor and delivery:
The potential effects of CHANTIX® on labor and delivery are not known.

Pediatric Use:
Safety and effectiveness of CHANTIX® in pediatric patients have not been established; therefore, CHANTIX® is not recommended for use in patients under 18 years of age.

Geriatric Use:
A combined single and multiple-dose pharmacokinetic study demonstrated that the pharmacokinetics of 1 mg varenicline given QD or BID to 16 healthy elderly male and female smokers (aged 65-75 yrs) for 7 consecutive days was similar to that of younger subjects. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Varenicline is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. No dosage adjustment is recommended for elderly patients.

Usual Dosage for Adults:
Smoking cessation therapies are more likely to succeed for patients who are motivated to stop smoking and who are provided additional advice and support. Patients should be provided with appropriate educational materials and counseling to support the quit attempt. The patient should set a date to stop smoking. CHANTIX® dosing should start one week before this date. CHANTIX® should be taken after eating and with a full glass of water. The recommended dose of CHANTIX® is 1 mg twice daily following a 1-week titration as follows: Days 1-3: 0.5 mg once daily Days 4-7: 0.5 mg twice daily Day 8-End of treatment: 1 mg twice daily Patients who cannot tolerate adverse effects of CHANTIX® may have the dose lowered temporarily or permanently. Patients should be treated with CHANTIX® for 12 weeks. For patients who have successfully stopped smoking at the end of 12 weeks, an additional course of 12 weeks treatment with CHANTIX® is recommended to further increase the likelihood of long-term abstinence. Patients who do not succeed in stopping smoking during 12 weeks of initial therapy, or who relapse after treatment, should be encouraged to make another attempt once factors contributing to the failed attempt have been identified and addressed.

Overdose:
If overdose is suspected, contact your local poison control center or emergency room immediately.

How to Pay:
We accept money orders and most types of credit cards. Your card will not be charged unless your prescription is approved. International customers are welcome: We accept orders and credit cards from both the U.S. and worldwide. Sorry: Checks or C.O.D.’s are not accepted.

Order Now

All Patients Must Complete an Online consultation:
The Online Consultation Form you complete will be reviewed by a physician. If the physician approves your use of Cialis®, the physician will send your prescription to a pharmacy which will fill your prescription and ship it right to your door.

Click here to place your order.

Existing Patients:
If you are seeking a refill of a prescription, you will need to complete another Medical Consultation Form which will be reviewed by a doctor. If the physician does not issue you a prescription for Cialis®, there will be NO charge for the order. Each time you request a refill, you will need to complete another Medical Consultation Form which will be reviewed by a physician.

Click here to place your re-order.

New Patients:
If this is the first time you are completing a Medical Consultation Form through KwikMed.com, you will not be charged a medical consultation or processing charge. If the physician does not issue you a prescription for Cialis®, there will be NO charge for the order. Each time you request a refill, you will need to complete another Medical Consultation Form which will be reviewed by a physician.

Click here to place your re-order.

Questions?
Contact us at service@kwikmed.com

For even more info visit one of the following sites:
www.pfizer.com
www.chantix.com

The name Chantix® is a registered trademark owned by Pfizer®, Inc. KwikMed.com is not affiliated with Pfizer®.